SightGlass Vision technology is intended to reduce the progression of myopia in children. Image: SightGlass Vision
The first SightGlass Vision myopic glasses begin to hit the market as EssilorLuxottica and CooperCompanies announce the launch of their joint venture.
Their collaboration is accelerating the commercialization of new eyeglass lens technologies to expand the category of myopia management.
SightGlass Vision’s Diffusion Optics Technology incorporates thousands of micro-dots in the lens that gently diffuse light to reduce contrast on the retina, which is intended to reduce the progression of myopia in children.
Mr. Norbert Gorny, co-CEO of EssilorLuxottica, said the company was “delighted” to see the progress of the innovative product.
“As a global leader with 30 years of experience in myopia research, we have been developing the myopia management category for over a decade. As such, we are excited to see our joint venture with CooperCompanies come to life as SightGlass Vision begins operating and the first products begin to hit the market.
“Together with eye care professionals, we will be able to raise awareness of existing solutions and improve access to technologies that can help children today and in their future lives,” Gorny said.
Mr. Dan McBride, COO and General Counsel at CooperCompanies, shared Gorny’s enthusiasm for the growth of the global myopia management category.
“Adding eyeglass lenses with SightGlass Vision technology to our portfolio of myopia management products results in better sight and brighter lives for countless children,” he said.
“SightGlass Vision’s commitment to clinic-based performance aligns well with CooperVision, which has conducted the world’s longest-running myopia management clinical study and is committed to establishing myopia management as a standard of care for affected children.
The last few decades have seen a steady increase in the prevalence of myopia around the world, particularly as a result of changing lifestyles. Affecting 2.6 billion people worldwide today, it is estimated that nearly 5 billion people – half of the world’s population – will be myopic by 2050.
Research shows that myopia is the leading cause of visual impairment in children and over time can contribute to an increased risk of developing permanent visual impairment, including macular degeneration, retinal detachment, cataracts and glaucoma, and blindness associated with high myopia.
New Data Confirms It’s Never Too Late to Start Myopia Treatment
CooperVision and Essilor announce a joint venture to acquire a spectacle lens for myopes
WCO and CooperVision develop myopia management resource